Multidisciplinary Team Tackles Personalized Medicine for Melanoma Patients with Normal BRAF Gene


A group of melanoma researchers and clinicians have received funding to address an important question in melanoma treatment: are there molecular targets for melanomas that do not harbor a mutation in the BRAF gene? And can we identify drug candidates for these new molecular targets? The Stand Up to Cancer (SUC2) philanthropic program and the Melanoma Research Alliance are jointly funding the 3-year, eight-institution endeavor. Continue reading…